<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Contagion Live articles</title><description>Contagion Live articles</description><link>https://www.contagionlive.com/news</link><category>Contagion Live articles</category><copyright>© 2026 MJH Life Sciences™ and Contagion Live. All rights reserved.</copyright><lastBuildDate>Sat, 15 Aug 2026 17:40:28 +0000</lastBuildDate><ttl>5</ttl><atom:link href="https://www.contagionlive.com/rss.xml" rel="self" type="application/rss+xml"/><language>en-us</language><image><title>Contagion Live articles</title><width>144</width><height>47</height><link>https://www.contagionlive.com/news</link><url>https://www.contagionlive.com/logo.webp</url></image><item><title>&lt;![CDATA[This Week&apos;s Top 5 Infectious Disease News Stories: August 8-August 14, 2026]]&gt;</title><link>https://www.contagionlive.com/view/this-week-s-top-5-infectious-disease-news-stories-august-8-august-14-2026</link><guid isPermaLink="true">https://www.contagionlive.com/view/this-week-s-top-5-infectious-disease-news-stories-august-8-august-14-2026</guid><description>&lt;![CDATA[This week&apos;s infectious disease news spans a broad-spectrum carbapenem review, an expanding jalapeño-linked salmonella recall, the EU approval of Maviret for acute hepatitis C, and clinician backlash against President Trump&apos;s executive order reshaping the childhood vaccine schedule.]]&gt;</description><pubDate>Sat, 15 Aug 2026 14:54:49 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[How New “Shared Clinical Decision Making” Vaccine Category Will Likely Increase Children’s Disease ]]&gt;</title><link>https://www.contagionlive.com/view/how-new-shared-clinical-decision-making-vaccine-category-will-likely-increase-children-s-disease</link><guid isPermaLink="true">https://www.contagionlive.com/view/how-new-shared-clinical-decision-making-vaccine-category-will-likely-increase-children-s-disease</guid><description>&lt;![CDATA[In the second part of the interview with Sharon Nachman, MD, she touches upon how the administration’s shared clinical decision-making category related to childhood vaccines will affect the hepatitis B and rotavirus vaccines and the expectations there will be subsequent disease increases. ]]&gt;</description><pubDate>Fri, 14 Aug 2026 13:16:53 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Cascading Effects of Executive Order on Childhood Vaccines]]&gt;</title><link>https://www.contagionlive.com/view/cascading-effects-of-executive-order-on-childhood-vaccines</link><guid isPermaLink="true">https://www.contagionlive.com/view/cascading-effects-of-executive-order-on-childhood-vaccines</guid><description>&lt;![CDATA[Jason M. Goldman, MD, MACP, discusses the potentially damaging effects of the rhetoric coming from the presidential executive order including downstream  consequences as well as his concerns around the prospective findings of the HHS Task Force on Safer Childhood Vaccines associated with it.   ]]&gt;</description><pubDate>Thu, 13 Aug 2026 15:59:17 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[The Potential Ramifications of Changing the MMR Vaccine Into 3 Separate Immunizations]]&gt;</title><link>https://www.contagionlive.com/view/the-potential-ramifications-of-changing-the-mmr-vaccine-into-3-separate-immunizations</link><guid isPermaLink="true">https://www.contagionlive.com/view/the-potential-ramifications-of-changing-the-mmr-vaccine-into-3-separate-immunizations</guid><description>&lt;![CDATA[The presidential executive order changing the measles, mumps and rubella (MMR) vaccine from a combination to a single-antigen vaccine means children will get more shots not less. Sharon Nachman, MD, offers some insights around the challenges of how the order’s latest changes could affect pediatric vaccine schedules. ]]&gt;</description><pubDate>Wed, 12 Aug 2026 18:20:23 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Working Towards Hepatitis C Elimination ]]&gt;</title><link>https://www.contagionlive.com/view/working-towards-hepatitis-c-elimination</link><guid isPermaLink="true">https://www.contagionlive.com/view/working-towards-hepatitis-c-elimination</guid><description>&lt;![CDATA[The EU recently approved glecaprevir/pibrentasvir (Maviret), an eight-week direct-acting antiviral regimen, which offers people with hepatitis C the fastest treatment option available, giving European health systems a new tool in aiding the World Health Organization&apos;s goal of eliminating the virus by 2030.]]&gt;</description><pubDate>Wed, 12 Aug 2026 11:13:59 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[FDA Accepts NDA for Lonafarnib to Treat Chronic Hepatitis D]]&gt;</title><link>https://www.contagionlive.com/view/fda-accepts-nda-lonafarnib-chronic-hepatitis-d</link><guid isPermaLink="true">https://www.contagionlive.com/view/fda-accepts-nda-lonafarnib-chronic-hepatitis-d</guid><description>&lt;![CDATA[The FDA has accepted EIT Pharma&apos;s new drug application for lonafarnib, an investigational oral therapy for chronic hepatitis D, supported by the phase 3 D-LIVR study, the largest clinical trial conducted to date in the disease.]]&gt;</description><pubDate>Tue, 11 Aug 2026 18:00:18 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Salmonella Outbreak Tied to Jalapeños Expands Downstream Recalls ]]&gt;</title><link>https://www.contagionlive.com/view/salmonella-outbreak-tied-to-jalape-os-expands-downstream-recalls</link><guid isPermaLink="true">https://www.contagionlive.com/view/salmonella-outbreak-tied-to-jalape-os-expands-downstream-recalls</guid><description>&lt;![CDATA[FDA continues its investigation of a Salmonella outbreak spanning across 27 states, with a recall that has expanded to include products that have jalapeños and sold at major retailers. ]]&gt;</description><pubDate>Tue, 11 Aug 2026 15:53:49 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Presidential Executive Order Changes Childhood Vaccine Schedule to Reflect Current Administration&apos;s Aims]]&gt;</title><link>https://www.contagionlive.com/view/presidential-executive-order-changes-childhood-vaccine-schedule-to-reflect-current-administration-s-aims</link><guid isPermaLink="true">https://www.contagionlive.com/view/presidential-executive-order-changes-childhood-vaccine-schedule-to-reflect-current-administration-s-aims</guid><description>&lt;![CDATA[President Trump signed an order spacing the timing of immunizations, limiting the number of vaccines, and changing the MMR vaccine by separating it into 3 single-antigen vaccines.   

]]&gt;</description><pubDate>Tue, 11 Aug 2026 13:56:41 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Expanding Hepatitis C Treatment: EU Approves Maviret ]]&gt;</title><link>https://www.contagionlive.com/view/expanding-hepatitis-c-treatment-eu-approves-maviret</link><guid isPermaLink="true">https://www.contagionlive.com/view/expanding-hepatitis-c-treatment-eu-approves-maviret</guid><description>&lt;![CDATA[The European Commission has approved glecaprevir/pibrentasvir (Maviret) for acute hepatitis C virus (HCV) infection, making it the only therapy approved in the European Union for both acute and chronic HCV and allowing clinicians to test and treat patients at the point of diagnosis. Mudra Kapoor, MD, discusses the phase 3 data and the treatment&apos;s potential role for greater HCV elimination. ]]&gt;</description><pubDate>Mon, 10 Aug 2026 11:56:09 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Preventing Hepatitis B Vertical Transmission ]]&gt;</title><link>https://www.contagionlive.com/view/preventing-hepatitis-b-vertical-transmission</link><guid isPermaLink="true">https://www.contagionlive.com/view/preventing-hepatitis-b-vertical-transmission</guid><description>&lt;![CDATA[An estimated 172,000 infants acquired hepatitis B virus through mother-to-child transmission in the WHO African region in 2022, and combining birth-dose vaccination with maternal antiviral prophylaxis could cut this burden by more than 86%. Peyton Thompson, MD, MSCR, discusses the barriers to eliminating vertical transmission of hepatitis B, and strategies to reduce the coverage gap. ]]&gt;</description><pubDate>Sun, 09 Aug 2026 13:42:43 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Review of Intravenous Carbapenems and Oral Tebipenem Pivoxil ]]&gt;</title><link>https://www.contagionlive.com/view/review-of-intravenous-carbapenems-and-oral-tebipenem-pivoxil</link><guid isPermaLink="true">https://www.contagionlive.com/view/review-of-intravenous-carbapenems-and-oral-tebipenem-pivoxil</guid><description>&lt;![CDATA[Here is a brief clinical overview of the single-agent intravenous carbapenems available in the United States (ertapenem, meropenem, and imipenem-cilastatin) and the recently approved oral carbapenem tebipenem pivoxil. ]]&gt;</description><pubDate>Sat, 08 Aug 2026 09:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Global Study Gauges Actual and Optimal Antibiotic Use ]]&gt;</title><link>https://www.contagionlive.com/view/global-study-gauges-actual-and-optimal-antibiotic-use</link><guid isPermaLink="true">https://www.contagionlive.com/view/global-study-gauges-actual-and-optimal-antibiotic-use</guid><description>&lt;![CDATA[International study estimates actual and optimal use of WHO AWaRe Access, Watch, and Reserve antibiotic classes in 186 countries and regions.]]&gt;</description><pubDate>Fri, 07 Aug 2026 13:11:22 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Foodborne Infections: The Latest on Cyclosporiasis, Salmonella, and Avocado Inspections ]]&gt;</title><link>https://www.contagionlive.com/view/foodborne-infections-the-latest-on-cyclosporiasis-salmonella-and-avocado-inspections</link><guid isPermaLink="true">https://www.contagionlive.com/view/foodborne-infections-the-latest-on-cyclosporiasis-salmonella-and-avocado-inspections</guid><description>&lt;![CDATA[A food-safety roundup covers a growing multistate cyclosporiasis outbreak including thousands more reported sickened and  2 deaths tied to iceberg lettuce, a Salmonella Javiana outbreak with hundreds of cases across 27 states linked to jalapeño peppers served at Chipotle and QDOBA, and the US suspension of avocado inspections in Michoacan, Mexico.]]&gt;</description><pubDate>Thu, 06 Aug 2026 15:21:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Immunization Updates from Moderna, Merck]]&gt;</title><link>https://www.contagionlive.com/view/immunization-updates-from-moderna-merck</link><guid isPermaLink="true">https://www.contagionlive.com/view/immunization-updates-from-moderna-merck</guid><description>&lt;![CDATA[The FDA has approved Moderna&apos;s influenza vaccine and set a Prescription Drug User Fee Act (PDUFA) date for Merck&apos;s RSV immunization product for expansion for a second season.]]&gt;</description><pubDate>Thu, 06 Aug 2026 12:42:58 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[H5N1 Genotype D1.1 Spread Rapidly Across US Flyways in 2024]]&gt;</title><link>https://www.contagionlive.com/view/h5n1-genotype-d1-1-spread-rapidly-across-us-flyways-in-2024</link><guid isPermaLink="true">https://www.contagionlive.com/view/h5n1-genotype-d1-1-spread-rapidly-across-us-flyways-in-2024</guid><description>&lt;![CDATA[A phylodynamic analysis combining Arizona wild bird surveillance with national sequence data found the H5N1 D1.1 genotype spread in a stepwise pattern among adjacent US flyways during fall 2024, with limited direct exchange between the Pacific and Atlantic flyways.]]&gt;</description><pubDate>Wed, 05 Aug 2026 17:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Serologic Study Finds Hantavirus Exposure in Northwestern Italy]]&gt;</title><link>https://www.contagionlive.com/view/serologic-study-finds-hantavirus-exposure-northwestern-italy</link><guid isPermaLink="true">https://www.contagionlive.com/view/serologic-study-finds-hantavirus-exposure-northwestern-italy</guid><description>&lt;![CDATA[A serologic study of patients in northwestern Italy found hantavirus antibodies in 7.3% of samples tested, with neutralization data suggesting Puumala virus as the likely infecting strain in a region where rodent-borne viral infections are rarely diagnosed.]]&gt;</description><pubDate>Wed, 05 Aug 2026 12:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[No HIV Infections Seen With Cabotegravir PrEP in Real-World Study]]&gt;</title><link>https://www.contagionlive.com/view/no-hiv-infections-cabotegravir-prep-real-world-study</link><guid isPermaLink="true">https://www.contagionlive.com/view/no-hiv-infections-cabotegravir-prep-real-world-study</guid><description>&lt;![CDATA[A real-world analysis of the OPERA cohort found no HIV infections among 315 women using long-acting cabotegravir for PrEP, despite frequent short delays in maintenance injections, reinforcing the regimen&apos;s real-world effectiveness.]]&gt;</description><pubDate>Tue, 04 Aug 2026 17:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Cabenuva Beats Daily Oral Therapy in Adolescents With HIV in LATA Trial]]&gt;</title><link>https://www.contagionlive.com/view/cabenuva-beats-daily-oral-therapy-adolescents-hiv-lata-trial</link><guid isPermaLink="true">https://www.contagionlive.com/view/cabenuva-beats-daily-oral-therapy-adolescents-hiv-lata-trial</guid><description>&lt;![CDATA[Week 96 data from the LATA trial show Cabenuva was superior to daily oral therapy in adolescents with HIV, while new real-world OPERA cohort data reinforce comparable effectiveness in adults, both presented at AIDS 2026.]]&gt;</description><pubDate>Tue, 04 Aug 2026 12:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Oral Antiviral GHP-88310 Blocks Measles-Like Transmission in Ferrets]]&gt;</title><link>https://www.contagionlive.com/view/oral-antiviral-ghp-88310-blocks-measles-transmission-ferrets</link><guid isPermaLink="true">https://www.contagionlive.com/view/oral-antiviral-ghp-88310-blocks-measles-transmission-ferrets</guid><description>&lt;![CDATA[An oral antiviral candidate blocked airborne and direct-contact transmission of a measles-like virus in ferrets, offering a potential new outbreak-control tool as US measles cases hit a 35-year high.]]&gt;</description><pubDate>Mon, 03 Aug 2026 17:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Bemnifosbuvir/Ruzasvir Meets Primary Endpoint in Phase 3 HCV Trial]]&gt;</title><link>https://www.contagionlive.com/view/bemnifosbuvir-ruzasvir-primary-endpoint-phase-3-hcv-trial</link><guid isPermaLink="true">https://www.contagionlive.com/view/bemnifosbuvir-ruzasvir-primary-endpoint-phase-3-hcv-trial</guid><description>&lt;![CDATA[Atea Pharmaceuticals&apos; bemnifosbuvir/ruzasvir combination met its primary endpoint of noninferiority to sofosbuvir/velpatasvir in the phase 3 C-BEYOND trial, achieving comparable cure rates for hepatitis C with as little as 8 weeks of treatment.]]&gt;</description><pubDate>Mon, 03 Aug 2026 12:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[IDSA Addresses Critical Questions on Staph aureus Bacteremia]]&gt;</title><link>https://www.contagionlive.com/view/idsa-addresses-critical-questions-on-staph-aureus-bacteremia</link><guid isPermaLink="true">https://www.contagionlive.com/view/idsa-addresses-critical-questions-on-staph-aureus-bacteremia</guid><description>&lt;![CDATA[2026 clinical practice guidelines developed by the IDSA and ESCMID address risk stratification, diagnosis and management of S aureus bacteremia.]]&gt;</description><pubDate>Sun, 02 Aug 2026 12:49:10 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Redefining HIV Management: Emerging Antiretroviral Drug Classes and Immunologic Strategies Shaping the Future of HIV Treatment, Prevention]]&gt;</title><link>https://www.contagionlive.com/view/redefining-hiv-management-emerging-antiretroviral-drug-classes-and-immunologic-strategies-shaping-the-future-of-hiv-treatment-prevention</link><guid isPermaLink="true">https://www.contagionlive.com/view/redefining-hiv-management-emerging-antiretroviral-drug-classes-and-immunologic-strategies-shaping-the-future-of-hiv-treatment-prevention</guid><description>&lt;![CDATA[Several combination products are currently in development for people with HIV. Here is a review of these treatments.]]&gt;</description><pubDate>Sat, 01 Aug 2026 13:39:15 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[H5N1: Have We Forgotten About Avian Influenza?]]&gt;</title><link>https://www.contagionlive.com/view/h5n1-have-we-forgotten-about-avian-influenza-</link><guid isPermaLink="true">https://www.contagionlive.com/view/h5n1-have-we-forgotten-about-avian-influenza-</guid><description>&lt;![CDATA[Despite competing national crises drawing attention elsewhere, experts warn that the ongoing H5N1 avian influenza outbreak in birds, cattle, and humans in the United States highlights critical gaps in surveillance, worker protections, and pandemic preparedness that must be addressed to prevent a future pandemic.]]&gt;</description><pubDate>Sat, 01 Aug 2026 10:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[FDA Says US Food Supply Safe as Cyclosporiasis Cases Top 11,000]]&gt;</title><link>https://www.contagionlive.com/view/fda-says-us-food-supply-safe-cyclosporiasis-cases-top-11000</link><guid isPermaLink="true">https://www.contagionlive.com/view/fda-says-us-food-supply-safe-cyclosporiasis-cases-top-11000</guid><description>&lt;![CDATA[FDA&apos;s acting deputy commissioner for food said the US food supply remains safe even as CDC-confirmed cyclosporiasis cases climbed past 11,000, while a new survey found nearly half of Americans don&apos;t trust the agency to manage the outbreak.]]&gt;</description><pubDate>Fri, 31 Jul 2026 14:00:56 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Sharon Nachman, MD, on How Pediatric AMR Forecasts Should Change Prescribing]]&gt;</title><link>https://www.contagionlive.com/view/sharon-nachman-pediatric-amr-forecasts-prescribing</link><guid isPermaLink="true">https://www.contagionlive.com/view/sharon-nachman-pediatric-amr-forecasts-prescribing</guid><description>&lt;![CDATA[Sharon Nachman, MD, chief of pediatric infectious disease at Stony Brook Children&apos;s Hospital, explains why local resistance data, not just global forecasts, should drive today&apos;s empiric antibiotic choices in children.]]&gt;</description><pubDate>Thu, 30 Jul 2026 14:30:53 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Global Study Finds Rising Antimicrobial Resistance in Children]]&gt;</title><link>https://www.contagionlive.com/view/global-study-finds-rising-antimicrobial-resistance-children</link><guid isPermaLink="true">https://www.contagionlive.com/view/global-study-finds-rising-antimicrobial-resistance-children</guid><description>&lt;![CDATA[A global surveillance study of more than 100,000 pediatric bacterial isolates found rising antimicrobial resistance across all regions from 2004 to 2022, with forecasts projecting continued increases in resistance to last-line antibiotics through 2035.]]&gt;</description><pubDate>Wed, 29 Jul 2026 16:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Long-Acting Injectable Buprenorphine Use Grows Unevenly Across US]]&gt;</title><link>https://www.contagionlive.com/view/buprenorphine-injectable-oud-treatment-access-disparities-health-affairs</link><guid isPermaLink="true">https://www.contagionlive.com/view/buprenorphine-injectable-oud-treatment-access-disparities-health-affairs</guid><description>&lt;![CDATA[A Rutgers Health study in Health Affairs found substantial growth in long-acting injectable buprenorphine prescriptions for opioid use disorder from 2021 to 2024, but with sharp state-level disparities driven by Medicaid policy differences, with fewer than 1% of buprenorphine prescribed as injectable in some states versus nearly 13% in others.]]&gt;</description><pubDate>Wed, 29 Jul 2026 11:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Ensitrelvir Becomes First Oral Option Available in US to Prevent COVID-19]]&gt;</title><link>https://www.contagionlive.com/view/xocova-shinogi-first-oral-option-us-prevent-covid-19</link><guid isPermaLink="true">https://www.contagionlive.com/view/xocova-shinogi-first-oral-option-us-prevent-covid-19</guid><description>&lt;![CDATA[Shionogi&apos;s XOCOVA (ensitrelvir) is now available in the United States as the first oral option to help prevent COVID-19 after exposure, following phase 3 SCORPIO-PEP trial data showing a 67% reduction in symptomatic infection risk.]]&gt;</description><pubDate>Tue, 28 Jul 2026 13:57:17 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Immune Modulation Shows Promise in Severe Disseminated Valley Fever]]&gt;</title><link>https://www.contagionlive.com/view/immune-modulation-valley-fever-coccidioidomycosis-disseminated</link><guid isPermaLink="true">https://www.contagionlive.com/view/immune-modulation-valley-fever-coccidioidomycosis-disseminated</guid><description>&lt;![CDATA[Three concurrent studies identify T cell exhaustion and Th2 skewing as distinct immune phenotypes in disseminated coccidioidomycosis, with targeted immunomodulation producing dramatic clinical responses in patients who had failed standard antifungal therapy.]]&gt;</description><pubDate>Tue, 28 Jul 2026 11:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Dovato Shows Noninferior Efficacy to Biktarvy in Head-to-Head HIV Trial]]&gt;</title><link>https://www.contagionlive.com/view/dovato-shows-noninferior-efficacy-to-biktarvy-in-head-to-head-hiv-trial</link><guid isPermaLink="true">https://www.contagionlive.com/view/dovato-shows-noninferior-efficacy-to-biktarvy-in-head-to-head-hiv-trial</guid><description>&lt;![CDATA[ViiV Healthcare&apos;s 2-drug Dovato regimen met its noninferiority end point against Gilead&apos;s 3-drug Biktarvy in the first head-to-head randomized trial comparing the 2 in treatment-naive adults with HIV.]]&gt;</description><pubDate>Mon, 27 Jul 2026 18:00:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item></channel></rss>